Success Metrics

Clinical Success Rate
87.0%

Based on 20 completed trials

Completion Rate
87%(20/23)
Active Trials
2(7%)
Results Posted
105%(21 trials)
Terminated
3(11%)

Phase Distribution

Ph early_phase_1
1
4%
Ph phase_2
9
33%
Ph phase_3
13
48%
Ph phase_4
3
11%
Ph phase_1
1
4%

Phase Distribution

2

Early Stage

9

Mid Stage

16

Late Stage

Phase Distribution27 total trials
Early Phase 1First-in-human
1(3.7%)
Phase 1Safety & dosage
1(3.7%)
Phase 2Efficacy & side effects
9(33.3%)
Phase 3Large-scale testing
13(48.1%)
Phase 4Post-market surveillance
3(11.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.0%

20 of 23 finished

Non-Completion Rate

13.0%

3 ended early

Currently Active

2

trials recruiting

Total Trials

27

all time

Status Distribution
Active(3)
Completed(20)
Terminated(3)
Other(1)

Detailed Status

Completed20
Terminated3
unknown1
Recruiting1
Active, not recruiting1
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
27
Active
2
Success Rate
87.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (3.7%)
Phase 11 (3.7%)
Phase 29 (33.3%)
Phase 313 (48.1%)
Phase 43 (11.1%)

Trials by Status

completed2074%
terminated311%
unknown14%
recruiting14%
active_not_recruiting14%
enrolling_by_invitation14%

Recent Activity

Clinical Trials (27)

Showing 20 of 27 trialsScroll for more
NCT07532876Phase 4

Comparison of Elagolix and OCPs in Reducing Endometriosis Associated Pelvic Pain

Enrolling By Invitation
NCT04333576Phase 3

Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain

Active Not Recruiting
NCT06076486Phase 3

A Clinical Trial to Evaluate Efficacy and Safety of Elagolix Tablets in Women With Moderate or Severe Endometriosis-associated Pain

Completed
NCT03271489Phase 3

Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

Completed
NCT03746535Early Phase 1

Cardiovascular Disease Risk in Women With Endometriosis

Recruiting
NCT05038878Phase 4

An Oral GnRH Antagonist to Treat Mild Autonomous Cortisol Excess (MACE) Due to Adrenal Adenomas in Postmenopausal Women

Terminated
NCT03213457Phase 3

A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain

Completed
NCT04039204Phase 2

Elagolix for Fertility Enhancement Clinical Trial

Completed
NCT04614246Phase 2

Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Comparison to an Inactive Pill (Placebo) and Elagolix in Women Suffering From Pain Related to a Condition Where the Tissue That Usually Grows Inside the Womb Grows Outside of the Womb

Terminated
NCT05648669Phase 3

A Study to Evaluate Safety and Efficacy of Elagolix in Patients With Moderate to Severe Endometriosis-Associated Pain

Unknown
NCT03951077Phase 2

Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome

Completed
NCT03886220Phase 4

A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

Completed
NCT02691494Phase 3

Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)

Completed
NCT02143713Phase 3

Global Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Women With Moderate to Severe Endometriosis-associated Pain

Completed
NCT01441635Phase 2

Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids

Completed
NCT02925494Phase 3

An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Completed
NCT01760954Phase 3

Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Adults With Moderate to Severe Endometriosis-Associated Pain

Completed
NCT01817530Phase 2

Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)

Completed
NCT02654054Phase 3

Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

Completed
NCT03343067Phase 3

A Study to Evaluate Safety and Efficacy of Elagolix in Participants With Endometriosis With Associated Moderate to Severe Pain

Terminated

Drug Details

Intervention Type
DRUG
Total Trials
27